Journal
JOURNAL OF IMMUNOLOGY
Volume 205, Issue 4, Pages 877-882Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2000676
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health [GM113681, R21AI142678]
- MRC [MR/N026993/1, MR/N013204/1] Funding Source: UKRI
Ask authors/readers for more resources
Despite high vaccine coverage in many parts of the world, pertussis is resurging in a number of areas in which acellular vaccines are the primary vaccine administered to infants and young children. This is attributed in part to the suboptimal and short-lived immunity elicited by acellular pertussis vaccines and to their inability to prevent nasal colonization and transmission of the etiologic agent Bordetella pertussis. In response to this escalating public health concern, the National Institute of Allergy and Infectious Diseases held the workshop Overcoming Waning Immunity in Pertussis Vaccines in September 2019 to identify issues and possible solutions for the defects in immunity stimulated by acellular pertussis vaccines. Discussions covered aspects of the current problem, gaps in knowledge and possible paths forward. This review summarizes presentations and discussions of some of the key points that were raised by the workshop.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available